Education
About Us
Working with TipRanks
Follow Us
Rezolute (RZLT)
NASDAQ:RZLT
RZLT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.66 - $6.19
Previous CloseN/A
Volume107.87K
Average Volume (3M)528.26K
Market Cap
$268.17M
Enterprise Value$232.03M
Total Cash (Recent Filing)$8.93M
Total Debt (Recent Filing)$1.93M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
May 20, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding60,535,423
10 Day Avg. Volume354,735
30 Day Avg. Volume528,264
Standard Deviation0.25
R-Squared0.00299
Alpha0.00422
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.45K
Enterprise Value/Ebitda-3.17
Forecast
1Y Price Target
$12.60Price Target Upside184.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Rezolute News
PremiumCompany Announcements
Rezolute’s Strategic Advances in Rare Disease Therapies
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsLimited clinical risk is seen based on positive data from the Ph2b RIZE study, which demonstrated statistically significant reductions in hypoglycemic events.
Regulatory ApprovalThe Breakthrough Therapy designation for ersodetug reflects the FDA's recognition of its promising efficacy in treating hypoglycemia due to congenital hyperinsulinism.
Bears Say
Financial PerformanceG&A expenses jumped 41.1% YoY to $4.5M, above the estimate of $4.1M, primarily due to an increase in professional fees and spending on increased headcount.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $1.66 and its highest was $6.18 in the past 12 months.
What is Rezolute’s market cap?
Rezolute’s market cap is $268.17M.
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is May 20, 2025 which is in 78 days.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on Feb 12, 2025. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.03.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate is -0.24.
How many shares outstanding does Rezolute have?
Rezolute has 60,535,423 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went down -1.029%.
Which hedge fund is a major shareholder of Rezolute?
Currently, no hedge funds are holding shares in RZLT
---
Rezolute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.60 (184.42% Upside)
$12.60 (184.42% Upside)
Blogger Sentiment
Bullish
RZLT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
173.45%
12-Months-Change
Fundamentals
Return on Equity
-71.43%
Trailing 12-Months
Asset Growth
9.65%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
---
RZLT Stock 12 Month Forecast
Average Price Target
$12.60
▲(184.42% Upside)
Technical Analysis
Best Analysts Covering RZLT
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
+55.37%
reiterated a buy rating 19 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of +55.37% per trade.
---